29 patents
Page 2 of 2
Utility
Pyrrolotriazine Compounds and Methods of Inhibiting Tam Kinases
7 Oct 20
Described herein are compounds, methods of making such compounds, pharmaceutical compositions, and medicaments comprising such compounds, and methods of using such compounds to treat cancer.
David Moebius, Jason J. Marineau, Yi Zhang, Kathryn Austgen, Claudio Edmundo Chuaqui, Goran Malojcic, William Sinko, Huiping Amy Guan, Tracey Lodie Savoie, Stephane Ciblat, Clint James, Amandine Xolin, Sylvain Bernard, Malay Doshi
Filed: 8 Oct 18
Utility
Tam Kinase Inhibitors
16 Sep 20
Described herein are compounds, methods of making such compounds, pharmaceutical compositions, and medicaments comprising such compounds, and methods of using such compounds to treat diseases, such as cancer.
Yi ZHANG, Claudio Edmundo CHUAQUE, Goran MALOJCIC, William SINKO, Stephane CIBLAT, Clint JAMES, Huiping Amy GUAN, Jason J. MARINEAU, David MOEBIUS
Filed: 12 Jul 18
Utility
Inhibitors of Cyclin-Dependent Kinase 7 (CDK7)
17 Jun 20
The present invention provides various compositions, including compounds of Formula (I) or (Ia), or a species thereof, and pharmaceutically acceptable salts, solvates (e.g., hydrates), stereoisomer, tautomers, isotopic and other specified forms thereof.
Jason J. Marineau, Michael Bradley, Claudio Edmundo Chuaqui, Stephane Ciblat, Anzhelika Kabro
Filed: 10 Feb 20
Utility
Compositions and Methods for Treating Cancers with Covalent Inhibitors of Cyclin-dependent Kinase 7 (CDK7)
15 Apr 20
The present invention relates to methods of identifying subjects suffering from various types of cancer who are more likely to respond to treatment with a covalent CDK7 inhibitor, such as N-((1S,3R)-3-(5-chloro-4-(1H-indol-3-yl)pyrimidin-2-ylamino)-1-methylcyclohexyl)-5-((E)-4-(dimethylamino)but-2-enamido)picolinamide (Compound 1), either alone or in combination with other classes of anti-cancer therapies based on the presence or absence of certain biomarkers.
Nisha Rajagopal, Graeme Hodgson, Emmanuelle Di Tomaso, Liv Helena Johannessen, Shanhu Hu
Filed: 11 Jun 18
Utility
Compositions of Cyclin Dependent Kinase 7 (CDK7) Inhibitor
8 Apr 20
The present invention provides, in part, compositions comprising an inhibitor of cyclin-dependent kinase 7 (CDK7) and sulfobutyl ether-β-cyclodextrin.
Neera Jain
Filed: 2 Apr 18
Utility
Tam Kinase Inhibitors
4 Mar 20
Described herein are compounds, methods of making such compounds, compositions (e.g., pharmaceutical compositions/medicaments) that include such compounds, and methods of using such compounds to treat diseases, such as cancer.
Yi Zhang, Kathryn Austgen, Claudio Chuaqui, Goran Malojcic, William Sinko, Huiping Amy Guan, Tracey Lodie Savoie
Filed: 12 Apr 18
Utility
Inhibitors of Cyclin-dependent Kinase 7 (CDK7)
8 Jan 20
Jason J. Marineau, Kevin Sprott, Darby Schmidt
Filed: 16 Jul 19
Utility
Inhibitors of Cyclin-dependent Kinase 7 (CDK7)
6 Nov 19
Stephane Ciblat, Anzhelika Kabro, Melissa Leblanc, Serge Leger, Jason J. Marineau, Tom Miller, Stephanie Roy, Darby Schmidt, M. Arshad Siddiqui, Kevin Sprott, Dana K. Winter, Amy Ripka, Dansu Li, Guoli Zhang
Filed: 14 May 19
Utility
Inhibitors of Cyclin-dependent Kinase 7 (CDK7)
30 Oct 19
Jason J. Marineau, Kevin Sprott, Darby Schmidt
Filed: 14 May 19